每周卡非佐米联合环磷酰胺和地塞米松治疗复发/难治多发性骨髓瘤:MCRN-003/MYX.1 单臂 II 期试验最终结果
MCRN-003/CCTGMYX.1 是一项单臂 II 期试验,评估每周卡非佐米、环磷酰胺和地塞米松(wKCd)方案在复发骨髓瘤中的疗效。主要终点为四周期后总缓解率,共纳入 76 例患者。结果显示 ORR 为 85%,中位 OS 和 PFS 分别为 27 个月和 17 个月,高危细胞遗传学患者缓解率和生存更差。
要点
- wKCd 方案在复发骨髓瘤中 ORR 达 85%,≥VGPR 为 68%。
- 高危细胞遗传学与更差 ORR 和 OS 相关。
- 常见≥3 级非血液学不良事件为感染、血管和心脏事件。
核心结论
- wKCd 是复发骨髓瘤安全有效的方案,尤其适用于不适合来那度胺治疗的患者。
研究设计与样本
- 单臂 II 期试验,纳入 76 例复发骨髓瘤患者,接受每周卡非佐米 20/70 mg/m2、地塞米松 40 mg 和环磷酰胺 300 mg/m2,28 天为一周期。
主要发现
- 总缓解率(ORR)为 85%,其中 ≥非常好部分缓解(VGPR)为 68%,≥完全缓解(CR)为 29%。
- 中位总生存期(OS)为 27 个月,中位无进展生存期(PFS)为 17 个月。
- 既往蛋白酶体抑制剂(PI)或来那度胺暴露不影响 OS 或 PFS。
- 15% 患者出现血清游离轻链(sFLC)逃逸,将其作为进展事件时中位 PFS 为 17 个月。
临床怎么用
- wKCd 方案可作为复发骨髓瘤的便捷无免疫调节剂(IMiD)选择,尤其适用于不适合来那度胺方案者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The MCRN-003/CCTGMYX.1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient immunomodulator (IMiD)-free regimen in relapsed myeloma. Weekly carfilzomib (20/70 mg/m2 ), dexamethasone 40 mg and cyclophosphamide 300 mg/m2 was delivered over 28-day cycles. The primary endpoint was overall response after four cycles. Secondary endpoints included toxicity, response depth, PFS and OS. Exploratory endpoints included the impact of cytogenetics, prior therapy exposure and serum free light chain (sFLC) escape; 76 patients were accrued. The ORR was 85% (68% ≥very good partial response [VGPR] and 29% ≥complete response [CR]). The median OS and PFS were 27 and 17 months respectively. High-risk cytogenetics conferred a worse ORR (75% vs. 97%, p = .013) and median OS (18 months vs. NR, p = .002) with a trend toward a worse median PFS (14 vs. 22 months, p = .06). Prior proteasome inhibitor (PI) or lenalidomide did not influence OS or PFS. The sFLC was noted in 15% of patients with a median PFS of 17 months when included as a progression event. The most common ≥ grade 3 non-hematologic adverse events were infectious (40%), vascular (17%) and cardiac (15%). The wKCD is a safe and effective regimen in relapse, especially for patients ineligible for lenalidomide-based therapies.
引用
- Venner CP, LeBlanc R, Sandhu I, et al. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial. Am J Hematol. 2021. PMID: 33650179. doi:10.1002/ajh.26147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。